

Korea drug dev fund joins hands with US CRO

23 October 2012 | News | By BioSpectrum Bureau

KDDF, WCCT announce mutual cooperation



Singapore: WCCT Global announced a mutual cooperation and business agreement with Korea Drug Development Fund (KDDF) located in Seoul, South Korea. This will be only the second global network of this kind between a US Contract Research Organization (CRO) and KDDF.

Through this alliance, KDDF hopes to seek help and to continue building ties for research institutions worldwide, in a cooperative effort for the development of new drugs, through educational forums, and training programs, between Korea and the US.

When interviewed, WCCT's CEO, Dr Kenneth T Kim stated that, "This is an exciting opportunity for WCCT Global to help Korean companies bring new medicinal products to the US and allow them to be represented and supported through the drug development process in the US."

In addition, Dr Kim said that, "We have been actively providing regulatory, drug development, and phase I/IIa services for Asian clients for nearly a decade, and we are extremely energized about the opportunity to work closely with Korean pharmaceutical companies wanting to develop new chemical entities (NCEs) globally starting in the US. With our access to Asian subjects, many Asian based clients can obtain their first in human data and Asian ethnic data in the same study, saving time and streamlining their global development plans."

KDDF's CEO, Dr Dongho Lee stated that, "It is meaningful that KDDF's effort to expand the global network is producing noticeable results. We hope that this agreement with WCCT will be another channel to provide important resources to the Korean investigators. We look forward to collaborating with WCCT to advance the drug development activities in Korea"